PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research

Abstract 4257: F5446 epigenetically reprograms T cells to boost CEA CAR T cell immunotherapy efficacy in human colorectal cancer metastasis

View Full Paper
Ask AI
Bookmark
Share

Authors

KFK. R. FickPCPatrick CzabalaZTZainab Tiamiyu

Discussion

Loading...

Member takes

Overview

Demonstrates that F5446 increases CAR T cell persistence in liver metastases, enhancing efficacy in colorectal cancer.

Key Points

  • To evaluate the efficacy of F5446 in enhancing CAR T cell therapy against colorectal cancer liver metastasis.
  • Developed SUV39H1 inhibitor F5446
  • Utilized α-CEA CAR T plasmids for lentivirus transduction
  • Implemented liver metastasis model in humanized mice
  • Administered F5446 treatment alongside CAR T cells
  • Analyzed CAR T cell phenotypes via flow cytometry
  • F5446 improved CAR T cell persistence in liver metastases compared to therapy without F5446
  • Increased levels of IFNγhi Tex-int cells observed
  • Combination therapy demonstrated a potential for enhanced efficacy against solid tumors

Cite This Study

Fick et al. (2026) studied this question.

synapsesocial.com/papers/69d1fc8ea79560c99a0a21a9https://doi.org/10.1158/1538-7445.am2026-4257
View Full Paper
Ask AI
Bookmark
Share